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Abstract
The causes of fungemia include immunosuppression and neutropenia stemming from diverse factors as well as the placement 
of central venous catheters. However, the relationship between fungemia and the oral cavity has not been substantiated. In 
this study, we explored the pathological conditions of Candida albicans—derived oral candidiasis in a mouse model, which 
always develops oral mucositis as a complication. In oral candidiasis, the hyphae of C. albicans are believed to primarily 
invade the stratum granulosum, but not the subepithelium, of the mucous membrane. We provide histological evidence that 
in concomitant oral mucositis, the hyphae infiltrate the subepithelium and blood vessels. Blood cultures and tissue samples 
revealed the onset of fungemia only in the mucositis-induced groups. Positive numbers of colony-forming units were found 
in groups A (chemotherapy), B (chemotherapy + mucositis) and C (mucositis), but were highest in group B. Some organs 
revealed positive CFU in groups B and C. The presence of fungal DNA in blood plasma and tissue was confirmed by PCR. 
The fungal DNA frequency was significantly higher in the mucositis group when compared with the non-mucositis group. The 
results suggest that fungi first invade the subepithelium and then the blood vessels, from which they disseminate throughout 
the body, and that oral mucositis is an important risk factor for fungemia. This study clearly demonstrates the relationship 
between oral mucositis, fungemia, and the potential systemic fungal dissemination, which has not been previously proven. 
Our findings highlight the importance of oral care for patients at risk of fungemia.
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Introduction
Superficial mycoses such as oral candidiasis can progress to 
deep mycoses such as fungemia, which are sometimes fatal. 
As these conditions can affect the success rate of cancer 
treatment, controlling their onset is vital. In oral candidi-
asis, Candida hyphae are generally believed to penetrate 
only the superficial layers of the mucous membrane. We 
have been exploring the pathogenicity of Candida albicans 
and Candida dubliniensis [1], and their influence on the 
mucous epithelium, by experimentally developing a mouse 
model of oral candidiasis. So far, hyphal infiltration of the 
subepithelium and subsequent deep mycosis has not been 
observed. However, oral mucositis is an adverse event that 
occurs in approximately 40% of patients receiving chemo-
therapy with anticancer medication, and in almost 100% 
of patients receiving radiotherapy to the oral area [2, 3]. 
Radiation-derived oral mucositis is reportedly aggravated 
by candidiasis [4]. Nevertheless, details such as the correla-
tion between these diseases and how mucositis progresses to 
deep mycosis that disseminates throughout the body remain 
unknown.
In the present study, we experimentally developed a new 
mouse model of oral candidiasis for reproducing human 
combination chemotherapy by intraperitoneal administration 
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of cisplatin (CDDP) and 5-fluorouracil (5-FU). Both are 
standard chemotherapy medications for head and neck can-
cer. To examine the effects of CDDP and 5-FU on oral can-
didiasis and the body, we experimentally ensured that the 
mice would contract oral mucositis as a complication of the 
treatments.
Materials and methods
The study was approved by the Animal Experimentation 
Ethics Committee of The Nippon Dental University School 
of Life Dentistry at Niigata (Approval No. 95).
Animals
Experimental animals were 8-week-old male ICR mice 
(CLEA Japan, Tokyo, Japan). The mice were housed at 
24 °C and given free access to food and water. For infec-
tion control, 0.83 g/L tetracycline hydrochloride (Waco 
Pure Chemical Industries, Tokyo, Japan) was added to the 
water. To prevent microbial contamination, all experimen-
tal apparatus, including litter and rearing containers, were 
sterilized in advance. Among the C. albicans strains held by 
the Advanced Research Center at the Nippon Dental Uni-
versity, Niigata, we selected the IFM40009 (ATCC 48130) 
strain, which yielded pathological factors of the fungus (high 
protease and phospholipase activity) [1]. The experimen-
tal mice were divided into four groups: group A (chemo-
therapy alone), group B (chemotherapy + mucositis), group 
C (mucositis alone), and a negative control group without 
microbial/drug administration and mucositis induction 
(n = 10 per group). Each group was orally inoculated with C. 
albicans (5.0 × 106 cells/25 µL) at 2, 3, and 5 days after start-
ing chemotherapy [5]. Separately from each experimental 
group, the white blood cell (WBC) count of non-inoculated 
mice was measured before and after chemotherapy using 
an automatic blood cell counting device (KX-21N; Sysmex 
Corp., Hyogo, Japan). This test ascertains changes in the 
WBC count induced by chemotherapy alone (n = 7). Starting 
from 1 day before chemotherapy (day 0), the body weight of 
each mouse was recorded at the same time every day.
Experimental schedule (Fig. 1)
Chemotherapy groups were intraperitoneally adminis-
tered 7 mg/kg CDDP (Nichi-Iko Pharmaceutical, Toyama, 
Japan) on day 1, and 10 mg/kg 5-FU (Kyowa Hakko Kirin, 
Co., Ltd., Tokyo, Japan) on days 1, 2, 3, and 4. Mucositis 
was induced as described by Yun-Sung et al. [6] and Fuji-
sawa et al. [7]. First, oral candidiasis in the mice (day 4 
of chemotherapy) was macroscopically ensured. Next, the 
mice were anesthetized with general anesthetic (concomitant 
pentobarbital and 2% xylazine hydrochloride), and surface 
anesthetic (xylocaine jelly) was applied to the tongue of each 
mouse. Finally, cotton swabs infused with 25 µL 50% ace-
tic acid were spotted on each side of the lingual border for 
30 s to 1 min. To remove any remaining drugs, the area was 
thoroughly washed with cotton swabs infused with sterile 
saline (Fig. 2). Once mucositis was induced, the mice were 
Day 1           Day 2         Day 3         Day 4    Day 5          Day 6  
Group A (chemotherapy alone)
Chemotherapya
Inoculated with C. ab
Sacrificedc
Group B (chemotherapy + mucositis)
Chemotherapya Sacrificedc
Inoculated with C. ab
Oral mucositis 
induced
Group C (mucositis alone)
Sacrificedc
Inoculated with C. ab
Oral mucositis 
induced
Day 1         Day 2        Day 3         Day 4       Day 5          Day 6  
Day 1          Day 2       Day 3         Day 4     Day 5          Day 6  
Fig. 1  Experimental schedule. a Chemotherapy groups were intra-
peritoneally administered 7  mg/kg CDDP on day 1, and 10  mg/kg 
5-FU on days 1, 2, 3, and 4. b Each group was then orally inoculated 
with C. albicans (5.0 × 106 cells/25 µL) 2, 3 and 5 days after starting 
chemotherapy, according to the method by Takakura et al. [5]. c On 
day 6, the mice were sacrificed and their organs (tongue, liver, and 
kidneys) and blood samples were collected aseptically from the car-
diac apex [8]
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given free access to food that was crushed into muddy pel-
lets with water. On day 6 of chemotherapy (5 days after 
inoculation), the mice were sacrificed by overdosing with 
general anesthetic (pentobarbital), and their organs (tongue, 
liver, and kidneys) and blood samples were collected asep-
tically from the cardiac apex [8]. After centrifugation 
(3000 rpm × 5 min), the plasma portion of the collected 
blood was sampled for polymerase chain reaction (PCR).
Culture and histological studies
After washing the organs with sterile saline and weighing 
them, half the sagittal section of the tongue, the right half 
of the kidney, and part of the liver near the bile duct were 
homogenized with sterile saline, yielding a 1-mL solution 
in a sterile micro-tube (BioMasher II; Assist, Tokyo, Japan). 
Subsequently, 100 µL of the solution was spread onto a Sab-
ouraud agar plate (Nissui Pharmaceutical, Tokyo, Japan) 
and incubated at 30 °C for 48 h. After incubation, colony-
forming units (CFU) were counted. The other half of the 
organ sample was immersed and fixed in 4% neutral buffered 
formalin solution for 48 h. After embedding in paraffin using 
the standard method, specimens were stained with hema-
toxylin–eosin (H–E) and periodic acid–Schiff (PAS) stains. 
The tongue specimens were additionally subjected to immu-
nohistochemical study (Von Willebrand factor staining).
Blood culture
Blood samples were aseptically collected upon death of the 
mice and incubated in peptone yeast extract glucose liquid 
medium at 30 °C for 72 h. Samples were then spread on 
a Sabouraud agar plate (Nissui Pharmaceutical, Co., Ltd., 
Tokyo, Japan) and incubated at 30 °C for 48 h. Follow-
ing culture (5 days in total), fungal growth was checked by 
observing colonies on the plate.
Molecular analysis
To check whether the strain in the blood, liver, and kid-
ney specimens that tested positive for CFU was identical 
to the inoculated strain, CFU strains were identified by 
multiplex PCR [9] (Table 1a). Similarly, the presence of 
C. albicans–specific DNA in blood plasma and tissue was 
detected by nested PCR. DNA was purified using DNA 
purification kits (Norgen Biotek Corp., Thorold, Canada) 
[10] (Table 1b).
A B C 
Fig. 2  a Day 0: before the experiment. b Day 4: mucositis was induced on both sides of the lingual border (arrowhead). The presence of oral 
candidiasis was indicated by white patches on the tongue (circle shown by a broken line). c Day 6: expansion of mucositis (white arrowhead)
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Statistical analysis
WBC counts were analyzed using Student’s t test. Body 
weights of mice were analyzed using two-way analysis of 
variance, tongue CFU were analyzed using Steel–Dwass 
multiple comparisons, and organ CFU were analyzed 
using Steel–Dwass multiple comparisons between each 
group, and Wilcoxon signed-rank tests between organs. 
Blood cultures and the results of nested PCR were ana-
lyzed using the Benjamini–Hochberg method for multiple 
comparisons. Statistical analyses were performed using the 
statistics add-in for BellCurve for Excell (Social Survey 
Research Information Co., Ltd, Tokyo, Japan), and R ver. 
3.3.2 software.
Results
Changes in WBC count and body weight
WBC counts were 2142 ± 292/µL (mean ± SD) in the chemo-
therapy (non-inoculated) group and 3542 ± 629/µL in the 
non-chemotherapy (healthy) group. Chemotherapy reduced 
the WBC count by approximately 39.5%. The difference 
between the chemotherapy group and the non-chemotherapy 
group was statistically significant (P < 0.01). In each group, 
weight loss was gradually observed from day 3 when com-
pared with the control group, and a significant difference 
was observed only in group B. At day 4, significant differ-
ences were observed between groups A, B, and C and the 
control group. Group B showed the most prominent weight 
loss among the groups.
Macroscopic findings
In all groups, typical lesions consisting of white patches 
on the tongue were gradually observed, and remained 
throughout the experiment. In addition, the lesions 
increased when oral mucositis was induced (Fig.  2, 
groups B and C).
Table 1  Sequence of PCR primers
Identification of Candida spp. Sequence (5′ to 3′) Gene name GenBank no. Ampli-
fied size 
(bp)
a. Oligonucleotides used in multiplex PCR [9]
 C. albicans albF GCT CGC ATA TAC CTG TCA TTG SAP5 AF043548 615
albR CGA GCT TGC CAT TTG AAT G
 C. dubliniensis dubF GGC TCA TCT ATT TTA GCT AC HWP1 AJ632273 416
dubR CCT GGA GCC GAT TCT GTA GT
 C. glabrata glaF ATG TCC ACT GAA AAC ACT TCT TTG ERG11 L40389 1006
glaR CTG GTC CTT TCA GCC AAA TGC 
 C. guilliermondii guiF GAT CCA CAG GAA CAT TAT CGATG XYL1 DQ297454 512
guiR CAT GAC TAA AAT GGA CCA C
 C. krusei kruF ACC TTG ATC CAG TTG CTT AC ABC1 DQ903906 1298
kruR CTC GTG GTA GTC CTG GTT C
 C. parapsilosis parF GCT GTT GGA TTG TGT CAT TCTG rCR DQ295067 833
parR GGC AAT TCC TTC AAT TTG GCAC 
 C. tropicalis troF GGA CGG GGG TAT GTT TCA ATT AAA TC ACT1 AJ237918 327
troR CCG ATT ACA GAT AAG TAA TTTCC 
Sequence (5′ to 3′) Fragment size 
(bp)
b. Primers used in nested PCR for C. albicans [10]
 Outer primer
  Sense TCC GTA GGT GAA CCT GCG G 750
  Antisense TCC TCC GCT TAT TGA TAT GC
 Inner primer
  Sense AAC TTG CTT TGG CGG TGG GC 386
  Antisense TGG ACG TTA CCG CCG CAA GC
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Histopathological findings
Breakdown of the basal layer was identical in groups B 
and C. In the same area, PAS staining confirmed that 
numerous fungi were present on the boundary between 
the damaged and unaffected sections of the basal layer. 
Fungi had invaded the subepithelium (Fig. 3b). Immuno-
histochemical staining (Von Willebrand factor staining) 
and PAS staining revealed intravascular hyphae in the 
vascular area (Fig. 3c–e).
Fungal counts in the tongue and organs
Fungal counts in the tongue were 2.51 ± 0.17 (mean ± SD) 
 log10CFU/mg in group A, 3.53 ± 0.10  log10CFU/mg in group 
B, and 2.85 ± 0.07  log10CFU/mg in group C. Counts were 
higher in group B when compared with the other groups. 
The differences between all groups were statistically sig-
nificant (Fig. 4a).
In the liver and kidneys, the mucositis-induced groups 
were CFU-positive, albeit at smaller numbers that were not 
statistically significant (Fig. 4b).
Blood culture
Ratios of CFU-positive specimens in blood cultures were 
0/10 (positive/total) in group A, 6/10 in group B, 3/10 in 
group C, and 0/10 in the negative control group. Fungemia 
occurred only in the mucositis-induced groups (groups B 
and C), and the incidence rate was higher in the group with 
concurrent chemotherapy (group B). Blood culture results 
(a) Histopathological findings of the tongue (bar = 200 μm). In each figure, the left side shows the tongue 
tip and the right side shows the tongue base. 






Fig. 3  a, b PAS staining (× 200). a Group A: the Candida hyphae 
have not progressed into the subepithelium (arrowhead). b Group 
B: a large amount of Candida hyphae invades the subepithelium of 
the tongue from the defective part of the basal layer (arrow). c, d 
H–E staining, Von Willibrand factor staining (× 400). Identification 
of blood vessels in the tissue; asterisk shows blood vessels. e Can-
dida hyphae infiltrate the blood vessels. PAS staining (× 400) (white 
arrow)
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were significantly different between groups A and B, and 
between group B and the negative control group.
Multiplex and nested PCR
Strains in blood serum, liver, and kidney specimens that 
tested positive for CFU in blood cultures were identified 
by multiplex PCR. All specimens harbored the inoculated 
C. albicans strain IFM40009 (Fig. 5b).
Although nested PCR revealed CFU-positive blood 
plasma specimens in all fungus-inoculated groups, the 
occurrence was more frequent in the mucositis-induced 
groups. The CFU-positive ratio was again higher in group 
B when compared with the other groups. A similar trend 
was observed in the liver and kidney specimens. All speci-
mens in the non-fungus-inoculated groups tested nega-
tive. The ratios in blood plasma, liver, and kidney speci-
mens were significantly different between groups A and 
B (Fig. 6a, b).
Fig. 4  a Tongue  log10 CFU/mg. 
The highest colony-forming unit 
(CFU) counts were obtained in 
group B. Between-group com-
parisons were statistically sig-
nificant (**P < 0.01). b Organ 
CFU/mg. CFU counts were 
lower in the liver and kidney 
specimens when compared with 
tongue specimens. No statisti-




















































Group Group A Group B Group C
Negative control
group
Positive no./total 0/10 6/10 3/10 0/10
1  2  3  4  5   6  7  8  9  10  11 ?615bpGroup B Group C? ?
* *
Fig. 5  a Blood culture analysis. Only the mucositis-induced groups 
(groups B and C) yielded positive results in blood culture (*P < 0.05). 
b Positive results of multiplex PCR for blood cultures. The 615  bp 
band specifically identifies Candida albicans among Candida spp. 
Lane 1: negative control (buffer), lane 2: positive control (C. albi-
cans), lanes 3–8: group B, and lanes 9–11: group C
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Discussion
Antineoplastic chemotherapy using CDDP and 5-FU in 
humans is the standard treatment for oral cancer [11, 12]. 
However, this treatment does have adverse effects, such as 
immunosuppression because of leukopenia and mucosi-
tis, which tend to occur almost simultaneously [2, 3, 13]. 
Furthermore, there have been clinical reports of fungemia 
occurring with CDDP and 5-FU chemotherapy [14].
The general procedure to create the murine model of oral 
candidiasis is to use chlorpromazine to adhere candida in 
the oral cavity. However, the fungus does not exist in the 
mouse as part of its normal flora, so even if it does adhere, 
it will be eliminated by the natural and cellular acquired 
immunity [15]. As such, it does not adhere for long and 
invasion of the hyphae are only known to reach the granular 
layer of the epithelium [16, 17]. In the current study, we 
succeeded in developing a mouse model of oral candidi-
asis by administering the immunosuppressant antineoplastic 
drugs CDDP and 5-FU in addition to chlorpromazine. 5-FU 
has antifungal effects, and flucytosine, an antifungal drug, 
is one of its prodrugs. For this reason, there is concern over 
the impact of its antifungal effect when administering 5-FU 
as an anticancer drug to create murine oral candidiasis. The 
minimal inhibitory concentration (MIC50) of 5-FU on C. 
albicans in vitro is reported to be 100 µg/mL [18]; however, 
when 200 mg/kg 5-FU was administered intraperitoneally 
to mice, the concentration in the blood was only 0.39 µg/
mL [19]. Therefore, we anticipated that the concentration 
of the drug we administered, expecting anticancer effects, 
would not impact the antifungal effect. In the current study, 
there were also oral candidiasis complications in mice in the 
chemotherapy-only group; therefore, we believe that this did 
not impact the experimental model.
Candida is not an indigenous oral microbe of the conven-
tional laboratory mouse [17]. We hypothesized that normal 
mouse oral bacterial flora may prevent C. albicans coloniza-
tion in the mouse oral cavity. Therefore, we used a relatively 
Fig. 6  a Lane a: negative 
control (buffer), lane b: positive 
control (C. albicans), lane to 
the right indicates positive or 
negative. b Occurrence (relative 
to all samples) was elevated in 
the mucositis-induced groups 
and was highest in group B. A 
similar trend was observed in 
liver and kidney specimens, but 
all specimens in the non-inoc-
ulated groups tested negative 
(*P < 0.05, **P < 0.01)
(a) Result of PCR for C. albicans (plasma)
(b) Summary
Plasma Liver Kidneys
Group A 4/10 5/10 4/10
Group B 10/10 10/10 10/10





? ? ? ? ? ? ? ? ? ? ?? ? ? ? ? ? ? ? ? ?? ? ? ? ? ? ? ? ? ?Group A
Negative control 
group
? ? ? ? ? ? ? ? ?
(a)  (b) 
(a)  (b) 
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high dose of tetracycline hydrochloride (0.83 g/L) to elimi-
nate the bacterial flora as soon as possible before the first 
inoculation of C. albicans in accordance with the method 
established by Takakura et al. [5].
We induced oral mucositis following the method by Sonis 
et al. [20] without physical stimulation, but with chemical 
stimulation using acetic acid to destroy the basal layer of the 
epithelium. We prepared the acetic acid solution at a 50% 
concentration based on the mucositis induction method by 
Yun et al. and Fujisawa et al. [6, 7]. With H–E staining, as 
we observed destruction only in the basal layer, we deter-
mined that we had succeeded in reproducing clinical oral 
mucositis.
Fungi are part of the normal flora of the human oral cav-
ity, skin, and urinary and enteral tracts, and the carrier rate 
increases with age [21, 22]. Fungi are known to be patho-
genic microorganisms causing septicemia and are reportedly 
observed in 15% of septicemia cases [23–26]. A delayed 
diagnosis can be lethal, and once a person is affected by 
fungemia, the fatality rate is high (40%). Other studies have 
reported that the rate is as high as 74% [27, 28]. The mor-
tality rate is also reported to increase with delayed intro-
duction of antifungal drug administration [29]. There are a 
variety of risk factors [30], and according to reports to date, 
placement of a central venous catheter is the most significant 
risk factor contributing to onset; however, there have been 
no studies that have elucidated the relationship with oral 
mucositis [31].
In the current study, our observations (fungal invasion 
into the subepithelium of the tongue and migration to the 
blood in a viable form, significant increases in the rate of 
fungemia onset, and discovery of viable fungus in certain 
organs) suggest that oral mucositis may be a pathway for 
fungi to enter the bloodstream. Using nested PCR, we found 
C. albicans DNA present in significant amounts in the blood 
and tissue in the presence of oral mucositis. It was also 
detected at significantly higher levels in the chemotherapy-
only group when compared with the control group. Using 
PCR, DNA of dead microorganisms can also be detected; 
therefore, it is not known whether specimens that tested 
positive had viable fungus at the time of tissue collection. 
Specific DNA detection suggests that fungemia occurred, 
even if transitory, and that some fungi were in deep tissue. 
From this experiment, we confirmed significant differences 
in blood cultures, blood plasma, and hepatic and renal find-
ings between the chemotherapy-only and chemotherapy and 
mucositis groups. This suggests the potential for complica-
tions when mucositis occurs during chemotherapy.
In the chemotherapy-only group, we did not observe the 
natural onset of mucositis; however, we observed fungemia 
in certain individuals. This suggests that the fungus may 
have entered either orally and proliferated after adhering; by 
direct entry via enteral tract mucositis, an adverse effect of 
anticancer drugs; or by the enteric–hepatic circulation; or it 
may have entered the blood by microbial translocation [32], 
among other possibilities, to migrate throughout the body.
Past studies have reported that pathogenic fungus and 
fungus detected from the oral cavity matched in 60% of 
clinical fungemia cases [33, 34]. In the current study, we 
found that oral mucositis was another important pathway 
for entry of fungus. Being a candida carrier is associated 
with poor oral hygiene; therefore, oral care is an important 
factor to control.
The study also suggests the importance of screening for 
carriers of fungus in addition to oral cavity management 
such as recontouring any sharp alveolar ridge and adjust-
ing ill-fitting dental prostheses, which can induce decubitus 
ulcers of the oral mucosa, prior to starting chemotherapy.
Conclusion
This study examined the relationship between oral candidi-
asis and hematogenous dissemination. As a result, In the 
presence of oral mucositis, fungi revealed the possibility of 
hematogenous dissemination. This suggests the importance 
of oral care not only for patients undergoing cancer treat-
ment but for all patients at risk of fungemia.
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